Study to Evaluate Safety and Pharmacokinetics of ARRY-403 in Patients With Type 2 Diabetes
| Status: | Archived |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2009 |
A Randomized, Double-Blind (Sponsor Excepted), Placebo-Controlled Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Orally Administered ARRY-403 in Patients With Type 2 Diabetes
Phase 1 study is designed to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics
(PD) of multiple ascending doses of ARRY-403 provided to patients with type 2 diabetes. The
study will consist of a Screening period, a Diary and Glucometer Dispensing Visit, a Washout
Period, a Confinement Period in the Clinical Research Unit, and a Follow-up/Termination
Visit.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials